AI Article Synopsis
- This study investigates the long-term effects of adjuvant therapy on different melanoma subtypes, particularly focusing on acral and mucosal types, using anti-PD-1 antibody and a combination of BRAF and MEK inhibitors.
- A total of 120 patients were analyzed, revealing a median time to relapse of 18.4 months, with acral and mucosal types having 3-year recurrence-free survival rates of 28.1% and 38.5%, respectively.
- Results indicate that adjuvant therapy is more effective for non-acral cutaneous melanoma compared to acral and mucosal types, especially regarding time to relapse.
Article Abstract
Background: Adjuvant therapy has improved the clinical prognosis for postoperative melanoma patients. However, the long-term efficacy of this therapy on the melanoma acral and mucosal subtypes has not been fully evaluated in previous trials. This study assessed the 3-year recurrence-free survival and overall survival of patients with melanoma, including the acral and mucosal subtypes, treated with anti-PD-1 antibody (Ab) or with the combination of the BRAF and MEK inhibitors dabrafenib and trametinib.
Methods: We retrospectively analyzed both the 3-year time to relapse (TTR) and overall survival (OS) of 120 patients treated with anti-PD-1 antibody (Ab), or with the combination of dabrafenib and trametinib.
Results: The overall median TTR was 18.4 months, with a range of 0.69 to 36 months. The 3-year TTR of the acral and mucosal types was 28.1% and 38.5%, respectively. Baseline tumor thickness (TT) and acral type were associated with the TTR in subgroup analysis. Moreover, we classified 104 acral and non-acral cutaneous patients into the anti-PD-1 Abs or dabrafenib plus trametinib combined therapies cohort in multiple analyses. The acral subtype and TT were detected as important prognostic factors. In the 3-year OS, only tumor ulceration was associated with the OS in both univariate and multiple analyses. There was no significant difference in baseline or treatment-related factors of the mucosal type ( > 0.05).
Conclusion: This study suggests that adjuvant therapy is more effective with non-acral cutaneous melanoma than either the acral or mucosal types at the 3-year TTR endpoint.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311258 | PMC |
| http://dx.doi.org/10.3390/cancers16152755 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
EClinicalMedicine
January 2025
Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.
Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).
The Roles of Vitamin D Receptor (VDR) and CD8+ T-Lymphocytes in Acral and Mucosal Melanoma Invasion Depth.
J Cutan Pathol
December 2024
Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjajaran, Dr. Hasan Sadikin General Hospital Bandung, Bandung, Indonesia.
Background: Acral and mucosal melanomas, the most common sun-shielded site melanoma subtypes in Asia and Indonesia, often yield poor prognoses. The invasion depth reflects their progressivity, and the pathogenesis is influenced by vitamin D receptor (VDR) status and CD8+ T-Lymphocyte amount. This study aims to determine the association between the invasion depth of acral and mucosal melanomas with their VDR and CD8+ immunoexpression.
View Article and Find Full Text PDFCyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy.
Molecules
November 2024
Department of Histology and Embryology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-067 Bydgoszcz, Poland.
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma.
View Article and Find Full Text PDFErythema multiforme.
EClinicalMedicine
November 2024
GrIDIST (Groupe Infectiologie et Infections Sexuellement Transmissibles) Working Group of the French Society of Dermatology, France.
Unlabelled: Erythema multiforme is an inflammatory skin and mucosal disease mainly related to infectious agents such as Herpes simplex virus, , though it can also be "idiopathic". The characteristic skin lesions are typical or atypical acral raised target lesions. The oral mucosa can be affected, alone or in combination with other mucosal/cutaneous sites, sometimes causing extreme pain, severely impacting food intake, and warranting hospitalization.
View Article and Find Full Text PDFGenetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan.
Cancer Med
November 2024
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Article Synopsis
- - Acral and mucosal melanomas are more common in Asians compared to Caucasians, while cutaneous melanomas are mainly found in Caucasians; this study focuses on the genetic traits of melanomas in Japanese patients due to under-research in this area.
- - Analysis of 104 Japanese melanoma samples revealed that 94% had driver mutations, with significant mutations differing among melanoma types: BRAF was notable in cutaneous, while acral exhibited mutations in KIT and others, and mucosal showed various driver mutations like NRAS and KRAS.
- - The findings suggest a lower tumor mutational burden in East Asian cutaneous melanoma, potentially impacting the effectiveness of immune checkpoint inhibitors and emphasizing the necessity for personalized treatment strategies based on
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!